id	metarevistapublica_asoneumocito_revistacolombianadeneumologia_28_article_44
record_format	ojs
spelling	Objetive: to compare the cost-effectiveness of budesonide/formoterol under SMART® therapy (160/4,5 μg one inhalation every 12 hours) versus fluticasone/salmeterol at fixed dose (25/125 μg two inhalations every 12 hours), in the management of patients with moderate persistent and severe persistent asthma, or who are at the third therapeutic step.Methods: cost-effectiveness was assessed through a Markov model that simulated the clinical stages of a patient with asthma, over a time horizon of one year and with a hypothetic cohort of 100 patients. Cost-effectiveness was assessed by taking avoided hospitalizations and months free from severe exacerbations as outcomes. The uses and costs related with each stage were calculated from the perspective of a third-party payer, beginning with information obtained from the databases of Colombian insurance service providers, at 2013 prices, and validated by specialists. An univariate and multivariate probabilistic sensitivity analysis was carried out.Results: SMART therapy reduced the number of hospitalizations by 5,7 with regard to fixed-dose salmeterol/fluticasone therapy. The number of months free of exacerbations for such therapy was 1.127, whereas that of salmeterol/fluticasone was 1.087.Conclusion: the use of budesonide/formoterol under SMART therapy reduces the total costs of management and maintenance, which significantly reduces the number of hospitalizations and increases the months without exacerbations. Thus, this treatment mode proves to be a more cost-effective option than salmeterol/fluticasone in the Colombian context. Romero, MD., MSc., PhD., Martín Huérfano, Odon., MSc., Lina Contreras, MD., Rubén Sánchez, MD., Oswaldo Upegui, Econ., MSc., Angie cost-effectiveness asthma budesonide/formoterol exacerbations avoided hospitalizations costo-efectividad asma budesonida/formoterol exacerbaciones hospitalizaciones evitadas 26 2 Artículo de revista Journal article 2016-08-11T23:34:07Z 2016-08-11T23:34:07Z 2016-08-11 application/pdf Asociación Colombiana de Neumología y Cirugía de Tórax Revista Colombiana de Neumología 0121-5426 2538-9513 https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/44 10.30789/rcneumologia.v26.n2.2014.44 https://doi.org/10.30789/rcneumologia.v26.n2.2014.44 spa https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Colombiana de Neumología - 2016 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. 61 62 https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/44/464 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_2df8fbb1 http://purl.org/redcol/resource_type/ART info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication
institution	ASOCIACION COLOMBIANA DE NEUMOLOGIA Y CIRUGIA DE TORAX
thumbnail	https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADENEUMOLOGIAYCIRUGIADETORAX/logo.png
country_str	Colombia
collection	Revista Colombiana de Neumología
description_eng	Objetive: to compare the cost-effectiveness of budesonide/formoterol under SMART® therapy (160/4,5 μg one inhalation every 12 hours) versus fluticasone/salmeterol at fixed dose (25/125 μg two inhalations every 12 hours), in the management of patients with moderate persistent and severe persistent asthma, or who are at the third therapeutic step.Methods: cost-effectiveness was assessed through a Markov model that simulated the clinical stages of a patient with asthma, over a time horizon of one year and with a hypothetic cohort of 100 patients. Cost-effectiveness was assessed by taking avoided hospitalizations and months free from severe exacerbations as outcomes. The uses and costs related with each stage were calculated from the perspective of a third-party payer, beginning with information obtained from the databases of Colombian insurance service providers, at 2013 prices, and validated by specialists. An univariate and multivariate probabilistic sensitivity analysis was carried out.Results: SMART therapy reduced the number of hospitalizations by 5,7 with regard to fixed-dose salmeterol/fluticasone therapy. The number of months free of exacerbations for such therapy was 1.127, whereas that of salmeterol/fluticasone was 1.087.Conclusion: the use of budesonide/formoterol under SMART therapy reduces the total costs of management and maintenance, which significantly reduces the number of hospitalizations and increases the months without exacerbations. Thus, this treatment mode proves to be a more cost-effective option than salmeterol/fluticasone in the Colombian context.
author	Romero, MD., MSc., PhD., Martín Huérfano, Odon., MSc., Lina Contreras, MD., Rubén Sánchez, MD., Oswaldo Upegui, Econ., MSc., Angie
spellingShingle	Romero, MD., MSc., PhD., Martín Huérfano, Odon., MSc., Lina Contreras, MD., Rubén Sánchez, MD., Oswaldo Upegui, Econ., MSc., Angie cost-effectiveness asthma budesonide/formoterol exacerbations avoided hospitalizations costo-efectividad asma budesonida/formoterol exacerbaciones hospitalizaciones evitadas
author_facet	Romero, MD., MSc., PhD., Martín Huérfano, Odon., MSc., Lina Contreras, MD., Rubén Sánchez, MD., Oswaldo Upegui, Econ., MSc., Angie
topic	cost-effectiveness asthma budesonide/formoterol exacerbations avoided hospitalizations costo-efectividad asma budesonida/formoterol exacerbaciones hospitalizaciones evitadas
topic_facet	cost-effectiveness asthma budesonide/formoterol exacerbations avoided hospitalizations costo-efectividad asma budesonida/formoterol exacerbaciones hospitalizaciones evitadas
topicspa_str_mv	costo-efectividad asma budesonida/formoterol exacerbaciones hospitalizaciones evitadas
citationvolume	26
citationissue	2
publisher	Asociación Colombiana de Neumología y Cirugía de Tórax
ispartofjournal	Revista Colombiana de Neumología
source	https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/44
language	spa
format	Article
rights	https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Colombiana de Neumología - 2016 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
type_driver	info:eu-repo/semantics/article
type_coar	http://purl.org/coar/resource_type/c_6501
type_version	info:eu-repo/semantics/publishedVersion
type_coarversion	http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content	Text
publishDate	2016-08-11
date_accessioned	2016-08-11T23:34:07Z
date_available	2016-08-11T23:34:07Z
url	https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/44
url_doi	https://doi.org/10.30789/rcneumologia.v26.n2.2014.44
issn	0121-5426
eissn	2538-9513
doi	10.30789/rcneumologia.v26.n2.2014.44
citationstartpage	61
citationendpage	62
url2_str_mv	https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/44/464
_version_	1811200688649142272

.

Código QR

Estadísticas y Métricas Alternativas

Títulos similares